Predicted Costs and Outcomes From Reduced Vibration Detection in People With Diabetes in the U.S.
- Arran Shearer, MSc1,
- Paul Scuffham, PHD1,
- Adam Gordois, MSC1 and
- Alan Oglesby, MPH2
- 1York Health Economics Consortium, University of York, York, U.K.
- 2Global Health Outcomes, Eli Lilly & Company, Indianapolis, Indiana
- Address correspondence and reprint requests to Arran Shearer, York Health Economics Consortium, Market Square, University of York, Vanbrugh Way, Heslington, York YO10 5NH, U.K. E-mail: as57{at}york.ac.uk
Abstract
OBJECTIVE—The ability to perceive vibration (vibration detection) has been shown to be a good predictor of the long-term complications of diabetic peripheral neuropathy (DPN). We aimed to estimate the predicted complications and costs for the U.S. health care system associated with reduced vibration detection (vibration perception threshold ≥25 V), estimated using a quantitative sensory testing device.
RESEARCH DESIGN AND METHODS—A Markov model was constructed for a hypothetical cohort of people with DPN. The model was run over a 10-year period using Monte Carlo simulations to estimate disease progression, predicted costs, and complications according to vibration detection levels.
RESULTS—The average individual with reduced vibration detection incurs approximately five times more direct medical costs for foot ulcer and amputations, yields 0.18 fewer quality-adjusted life-years, and lives for ∼2 months less than an average individual with normal vibration detection.
CONCLUSIONS—The treatment of foot ulceration and amputation is time-consuming and expensive. If individuals with reduced vibration detection could be identified, then preventative care could be concentrated on those patients, potentially saving valuable resources and improving health outcomes.
- DPN, diabetic peripheral neuropathy
- QALY, quality-adjusted life-year
- VPT, vibration perception threshold
Footnotes
-
A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.
-
- Accepted May 9, 2003.
- Received October 10, 2002.
- DIABETES CARE











